U.S. Capital Wealth Advisors, LLC Editas Medicine, Inc. Transaction History

U.S. Capital Wealth Advisors, LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 12, 2022	SELL	$14.08 - $27.63 $985 - $1,934	-70 Reduced 0.32%	21,593 $411,000
Q4 2021 Jan 21, 2022	BUY	$26.55 - $40.57 $1,858 - $2,839	70 Added 0.32%	21,663 $575,000
Q3 2021 Nov 01, 2021	BUY	$39.27 - $72.94 $847,957 - $1.57 Million	21,593 New	21,593 $887,000

228

54.2M

412K

355K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of U.S. Capital Wealth Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on U.S. Capital Wealth Advisors, LLC with notifications on news.